You just read:

BioMarin Receives Access to Priority Medicines (PRIME) Regulatory Support from EMA for BMN 270 Gene Therapy in Hemophilia A

News provided by

BioMarin Pharmaceutical Inc.

Feb 01, 2017, 16:15 ET